Drug Database
ES

esmolol hydrochoride

✓ Approved

HQ Specialty Pharma · ADRB1 · Small Molecule

What is esmolol hydrochoride?

esmolol hydrochoride is a small molecule developed by HQ Specialty Pharma. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyHQ Specialty Pharma
Drug ClassSmall Molecule
Molecular TargetADRB1
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

esmolol hydrochoride acts on 1 molecular target:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

esmolol hydrochoride is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersAtrial fibrillation✓ Approved
Vascular disordersHypertension✓ Approved
Cardiac disordersSupraventricular tachycardia✓ Approved

Related Research Articles

PubMedAnesthesiology research and practice2026-08-30

Intraoperative Hemodynamic Management and Cerebral Protection During Awake Craniotomy: Evidence-Based Approaches.

Maragh Marc Knezevic MK, Garcia Alanna Pagan AP, Oliinyk Yuliia Y, Acharjee Jayottri J et al.

Awake craniotomy is a standard neurosurgical technique that enables real-time assessment of brain functions during tumor resection, with high success rates. Although highly effective, the procedure is associated with hemodynamic disturbances, including blood pressure variability and impaired cerebral perfusion, compromising intraoperative safety. A focused literature search of PubMed, Embase, and Google Scholar was performed to identify relevant studies on intraoperative hemodynamic management during awake craniotomy. Findings were synthesized narratively to summarize current evidence, highlight emerging strategies, and identify knowledge gaps. Hypertension (8%-34%) was the most common disturbance, often triggered by painful surgical stimuli or emergence from sedation, with repeat craniotomy, impaired autoregulation, and glioma pathology as additional risk factors. Hypotension (10%-11%) was linked to perioperative stroke and mortality. Cerebral hypoperfusion contributed to poor outcomes, with stroke up to 23% and neurological morbidity in 68% of patients. Preventive strategies, such as scalp blocks, individualized blood pressure targets, and the use of dexmedetomidine and midazolam, improved intraoperative stability, while short-acting agents, including esmolol and labetalol, were preferred for rapid control. Advanced monitoring modalities, including arterial lines, near-infrared spectroscopy, and cerebral autoregulation indices, enhance safety and support accurate functional mapping. Hemodynamic instability during awake craniotomy influences outcomes. Current evidence supports multimodal prevention, tailored blood pressure control, and short-acting pharmacological agents; practice variation and the lack of randomized trials limit standardization. Looking ahead, advanced monitoring and emerging AI systems may provide new opportunities to enhance cerebral protection and optimize patient safety. This review summarizes evidence on intraoperative hemodynamic control in awake craniotomy, emphasizing strategies that enable maximal safe resection while preserving neurological function.

PubMedWorld journal of methodology2026-08-21

Comparison of propofol alone vs propofol-phenylephrine combination for intraoperative hemodynamic stability in glioma surgery.

Thotungal Rhea R, Kaushal Ashutosh A, Agrawal Amit A, Jain Anuj A et al.

Propofol is widely used for induction in glioma surgery for its neuroprotective effects and favorable recovery profile. However, its dose-dependent hypotension is a major limitation in procedures requiring stable cerebral perfusion. To compare the efficacy of propofol vs propofol-phenylephrine (PPE) combination in maintaining hemodynamic stability in patients undergoing glioma surgery. Ninety American Society of Anesthesiologists I-II patients scheduled for elective glioma surgery were randomized to receive either propofol (group P) or a PPE admixture (group PPE). Induction was performed with slow titration of the study drug until loss of verbal response and Bispectral index < 60, followed by a continuous infusion (50 μg/kg/minute) until skin closure. Hemodynamic parameters [mean arterial pressure (MAP), systolic blood pressure, diastolic blood pressure, and heart rate] were recorded at baseline, during induction, immediately after intubation, and at predefined intraoperative time points. The incidence of hypotension, vasopressor and esmolol use, and brain relaxation scores were compared. Group PPE demonstrated significantly better preservation of MAP, systolic blood pressure, diastolic blood pressure, and heart rate throughout the peri-induction and intraoperative periods (P < 0.05). The mean maximum MAP reduction during induction was greater in group P compared with group PPE (19.7 mmHg vs 12.5 mmHg; P < 0.01). Hypotensive episodes were significantly more frequent in group P than in group PPE (84.4% vs 6.7%; P < 0.001). Rescue phenylephrine requirements were markedly lower in group PPE (P < 0.001). Esmolol use and brain relaxation scores were comparable between groups. Adding phenylephrine to propofol for induction and maintenance provides superior hemodynamic stability without compromising brain relaxation in glioma surgery.

PubMedAcute and critical care2026-08-19

Esmolol in the management of refractory ventricular fibrillation: a systematic review and meta-analysis.

Lau Kathleen K, Chau Yau-Lam Alex YA, Cheng Ting-An TA, Lai Michael M et al.

Refractory ventricular fibrillation (rVF) presents a significant challenge in advanced cardiovascular life support (ACLS), with traditional antiarrhythmics showing limited success in improving long-term survival and neurological function. Esmolol, a beta-1 selective adrenergic receptor antagonist, might offer benefits due to its rapid onset and catecholamine-suppressing effects during cardiac arrest. This systematic review and meta-analysis (SRMA) evaluates the effectiveness of esmolol in improving the temporary return of spontaneous circulation (ROSC), sustained ROSC, survival to discharge, and survival to discharge with favorable neurological outcomes in rVF patients. This SRMA reviewed Medline (Ovid), Embase (Ovid), and Cochrane Central (Ovid) from their inception until October 2, 2025, for full-text clinical or observational studies assessing esmolol use alongside standard ACLS in adult rVF in both prehospital and in-hospital settings. The risk of bias was independently assessed using the Newcastle-Ottawa Scale. Pooled risk ratios (RRs; 95% CI) are reported. Analyses in which I² >50% used a random-effects model; otherwise, a common-effect model was used. Four studies (n=273) are included. Esmolol was associated with an increased temporary ROSC (RR, 1.80; 95% CI, 1.09-2.98), and although the links were not statistically significant, esmolol trended toward a benefit in sustained ROSC (RR, 1.25; 95% CI, 0.28-5.66), survival to discharge (RR, 1.08; 95% CI, 0.57-2.03), and survival to discharge with favorable neurological outcomes (RR, 2.08; 95% CI, 0.83-5.24). Esmolol was associated with improved temporary ROSC in rVF. The sensitivity analysis suggests potential benefits for sustained ROSC and neurological survival, but more data are needed. Further research is needed to clarify its role.

PubMedJournal of clinical medicine2026-08-13

Protective Effect of Esmolol on the Hypertensive Aortic Wall Persists After Withdrawal of Short-Term Treatment.

Fernández-Morales David D, Arnalich-Montiel Ana A, Delgado-Martos María J MJ, Rodríguez-Rodríguez Pilar P et al.

Background: Our research group has previously demonstrated the protective effect of short-term treatment with esmolol on large artery remodeling. However, whether this beneficial effect persists after treatment withdrawal remains unknown. Therefore, the aim of the present study was to investigate whether regression of thoracic aorta remodeling after a short-term esmolol treatment persists following drug withdrawal. Methods: Adult male spontaneously hypertensive rats (SHRs) received either esmolol (300 µg/kg/min) or vehicle (saline solution) by continuous infusion for 48 h. Following treatment, animals were evaluated either immediately (SHR-E 48 h group) or after withdrawal periods of 7 days (SHR-E 7 d group) or 1 month (SHR-E 1 m group). Hemodynamic parameters, thoracic aorta geometry, extracellular matrix composition (elastin and collagen), and the passive mechanical response of the arterial wall (β parameter) were assessed in all animals. Results: Forty-eight hours of esmolol treatment significantly reduced blood pressure and attenuated thoracic aortic wall thickness, external diameter, cross-sectional area, collagen content and elastic fiber density. Additionally, passive mechanical testing showed a significant reduction in the β parameter, indicating improved arterial compliance after treatment. Remarkably, these structural and mechanical benefits persisted for up to one month after withdrawal, despite the return of blood pressure to hypertensive levels. Conclusions: Protective effect of esmolol on aortic remodeling is persistent after treatment withdrawal in SHRs, perhaps independent of blood pressure.

PubMedAnesthesia and analgesia2026-08-11

Esmolol and Opioid Sparing: Analgesic Signal or Hemodynamic Silhouette?

Mistry Tuhin T, Nair Abhijit Sukumaran AS

PubMedMedicine2026-07-25

Effects of nicardipine and esmolol on regional renal oxygenation and hemodynamics during controlled hypotension in rhinoplasty: A prospective, randomized clinical trial.

Cintan Kamil K, Yüzkat Nureddin N, Demir Canser Yilmaz CY, Tunçdemir Yunus Emre YE

Achieving a bloodless surgical field during rhinoplasty is critical, yet the physiological impact of controlled hypotension (CH) on renal oxygenation remains a concern. This study evaluated the effects of nicardipine and esmolol on regional renal oxygenation and hemodynamics during controlled hypotension in patients undergoing rhinoplasty. After ethics approval and trial registration (ClinicalTrials.gov: NCT05430724), 80 adults with ASA I-II status undergoing elective rhinoplasty at a single university hospital were enrolled. Patients were assigned to group N (nicardipine, n = 40) or group E (esmolol, n = 40). Target mean arterial pressure (MAP) was 55 to 65 mm Hg. The primary outcomes were regional renal oxygenation (rSO2) measured using near-infrared spectroscopy and hemodynamics. Secondary outcomes included opioid requirements, renal function tests, and assessor-blinded surgical satisfaction. All 80 randomized patients completed the trial and were included in the final analysis. Repeated-measures analysis showed significant time-dependent changes in MAP and renal rSO2 values, with significant time × group interactions for MAP, right renal rSO2, and left renal rSO2. No prespecified renal desaturation events, defined as a ≥20% decrease from baseline rSO2, occurred in either group. Additional opioid use was significantly higher in group N (P = .001), whereas surgical satisfaction was more favorable in group E (P = .001). Postoperative creatinine and urea values remained within normal limits in both groups. In this short-duration rhinoplasty model, esmolol was associated with more favorable hemodynamic control, reduced opioid requirement, and higher surgical satisfaction compared with nicardipine. Although nicardipine was associated with higher regional renal rSO2 values, this finding should be interpreted as an exploratory physiological observation rather than evidence of functional renal protection. No external funding was received for this trial.

+1634 more articles available with a free account

Sign up free to view all articles →

Ask about esmolol hydrochoride